Effect of Unani formulations in Uterine Fibroid: A pre and post analytical study

Effect of Unani formulations Oral & Topical in uterine fibroid A pre and post analytical study - nil

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/01/079496

Enrollment

Registered

2025-01-27

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N938- Other specified abnormal uterine and vaginal bleeding

Interventions

Intervention1: Orally- Joshanda of Aslussoos, badiyan, badranjboya with Gulqand. Locally- Zimad of Tukhme Katan, Tukhme Hulba, Haloon and roughane bedanjeer : Oral- Aslussoos, badiyan, and badranjboy

Eligibility

Inclusion criteria

Inclusion criteria: Study participants with In age group of 20-50 years with uterine fibroid & Volume of Uterine fibroid more than or equal to 2cm3 to 20cm3 found on USG pelvis HMB PBAC more than 100 Dysmenorrhea VAS more than 5

Exclusion criteria

Exclusion criteria: Study participants with Pregnancy Severe symptomatic uterine fibroid PBAC more than 500 and VAS more than 8 Associated Endometriosis Adenomyosis and rapid tumor growth

Design outcomes

Primary

Measure	Time frame
Reduction in uterine fibroid volume on USG pelvisTimepoint: baseline and at 12 weeks	—

Secondary

Measure	Time frame
Improvement in PBAC and VAS score Improvement in Uterine Fibroid Symptom and Quality of Life Questionnaire (UFS-QOL) Timepoint: baseline and at 0,4,8,12 weeks	—

Countries

India

Contacts

Public ContactProf Ismath Shameem

National institute of unani medicine

dr.ismaths@gmail.com9449977008

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026